Kwang Myung Pharm

Kwang Myung Pharm is a South Korean pharmaceutical company that specializes in the production of active pharmaceutical ingredients (APIs) and finished drug products. Founded in 1957, the company has built a strong reputation in the domestic market for its expertise in chemical synthesis and GMP-compliant manufacturing. In 2011, it was acquired by the biotechnology firm Pharmicell, facilitating a strategic merger between traditional pharmaceutical manufacturing and advanced stem cell therapy development. Kwang Myung Pharm's product portfolio includes a diverse range of generics and APIs focusing on cardiovascular, gastrointestinal, and anti-infective therapeutic areas. The company operates significant manufacturing facilities in Wonju, providing both proprietary products and contract manufacturing services to the global healthcare industry.